An assessment of the direct and indirect costs of bladder cancer preceding and following a cystectomy: a real-world evidence study

REFERENCES

• National Cancer Institute. Bladder Cancer Treatment (PDQ®)–Health Professional Version. Updated 01/18/2023. Accessed 06/13/2023, https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq
   Google Scholar
• National Cancer Institute. Cancer Stat Facts: Bladder Cancer. Accessed 06/13/2023, https://seer.cancer.gov/statfacts/html/urinb.html
   Google Scholar
• Perera M, McGrath S, Sengupta S, Crozier J, Bolton D, Lawrentschuk N. Pelvic lymph node dissection during radical cystectomy for muscle-invasive bladder cancer. Nat Rev Urol. Nov 2018;15(11):686-692. doi: 10.1038/s41585-018-0066-1.
   Google Scholar
• Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. Nov 2009;182(5):2195-203. doi: 10.1016/j.juro.2009.07.016.
   Google Scholar
• Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. Mar 2006;49(3):466-5; discussion 475-7. doi: 10.1016/j.eururo.2005.12.031.
   Google Scholar
• Chen S, Zhu S, Cui X, et al. Identifying non-muscle-invasive and muscle-invasive bladder cancer based on blood serum surface-enhanced Raman spectroscopy. Biomed Opt Express. Jul 1 2019;10(7):3533-3544. doi: 10.1364/BOE.10.003533.
   Google Scholar
• Powles T, Bellmunt J, Comperat E, et al. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. Mar 2022;33(3):244-258. doi: 10.1016/j.annonc.2021.11.012.
   Google Scholar
• Bagheri I, Shan Y, Klaassen Z, et al. Comparing Costs of Radical Versus Partial Cystectomy for Patients Diagnosed With Localized Muscle-Invasive Bladder Cancer: Understanding the Value of Surgical Care. Urology. Jan 2021;147:127-134. doi: 10.1016/j.urology.2020.08.058.
   Google Scholar
• Williams SB, Howard LE, Foster ML, et al. Estimated Costs and Long-term Outcomes of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guerin in the Veterans Affairs Health System. JAMA Netw Open. Mar 1 2021;4(3):e213800. doi: 10.1001/jamanetworkopen.2021.3800.
   Google Scholar
• Nguyen PL, Gu X, Lipsitz SR, et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 04/20/2011 2011;29(12) doi: 10.1200/JCO.2010.31.1217.
   Google Scholar
• Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. Jan 19 2011;103(2):117-28. doi: 10.1093/jnci/djq495.
   Google Scholar
• Hoeh B, Flammia RS, Hohenhorst L, et al. Regional differences in total hospital costs for radical cystectomy in the United States. Surg Oncol. Jun 2023;48:101924. doi: 10.1016/j.suronc.2023.101924.
   Google Scholar
• Cleveland Clinic. Cystectomy. Updated 11/17/2022. Accessed 06/13/2023, https://my.clevelandclinic.org/health/treatments/21049-cystectomy
   Google Scholar
• Peyton CC, Reich RR, Tang D, et al. Identifying and Codifying Complications after Radical Cystectomy: Comparison of Administrative Diagnostic and Procedure Codes, and Clinical Chart Review. J Urol. Nov 2019;202(5):913-919. doi: 10.1097/JU.0000000000000398.
   Google Scholar
• Chua KJ, Patel HV, Srivastava A, et al. Annual trends of cystectomy complications: A contemporary analysis of the NSQIP database. Urol Oncol. May 26 2023; doi: 10.1016/j.urolonc.2023.03.014.
   Google Scholar
• Weinberg L, Aitken SAA, Kaldas P, et al. Postoperative complications and hospital costs following open radical cystectomy: A retrospective study. PLoS One. 2023;18(2):e0282324. doi: 10.1371/journal.pone.0282324.
   Google Scholar
• Mossanen M, Krasnow RE, Lipsitz SR, et al. Associations of specific postoperative complications with costs after radical cystectomy. BJU international. 2018;121(3):428-436.
   Google Scholar
• Mak KS, Smith AB, Eidelman A, et al. Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys. Dec 1 2016;96(5):1028-1036. doi: 10.1016/j.ijrobp.2016.08.023.
   Google Scholar
• Merative. Merative MarketScan Research Databases. Accessed June 17, 2024, https://www.merative.com/documents/brief/marketscan-explainer-general
   Google Scholar
• Barone B, Finati M, Cinelli F, et al. Bladder Cancer and Risk Factors: Data from a Multi-Institutional Long-Term Analysis on Cardiovascular Disease and Cancer Incidence. J Pers Med. Mar 13 2023;13(3) doi: 10.3390/jpm13030512.
   Google Scholar
• U.S. Bureau of Labor Statistics. Measuring Price Change in the CPI: Medical care. Updated 02/10/2023. Accessed 06/13/2023, https://www.bls.gov/cpi/factsheets/medical-care.htm
   Google Scholar
• Goetzel RZ, Long SR, Ozminkowski RJ, Hawkins K, Wang S, Lynch W. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.S. employers. J Occup Environ Med. Apr 2004;46(4):398-412. doi: 10.1097/01.jom.0000121151.40413.bd.
   Google Scholar
• Settipane RA, Kreindler JL, Chung Y, Tkacz J. Evaluating direct costs and productivity losses of patients with asthma receiving GINA 4/5 therapy in the United States. Ann Allergy Asthma Immunol. Dec 2019;123(6):564-572 e3. doi: 10.1016/j.anai.2019.08.462.
   Google Scholar
• Statistics UBoL. Consumer Price Index: Medical Care. Medical care in U.S. city average, all urban consumers, not seasonally adjusted. . https://www.bls.gov/cpi/factsheets/medical-care.htm
   Google Scholar
• Soliman AM, Taylor HS, Bonafede M, Nelson JK, Castelli-Haley J. Incremental direct and indirect cost burden attributed to endometriosis surgeries in the United States. Fertil Steril. May 2017;107(5):1181-1190 e2. doi: 10.1016/j.fertnstert.2017.03.020.
   Google Scholar
• Jerry M, Arcona S, McMorrow D, Schwartz H, Princic N, Sasane R. Work Loss and Direct and Indirect Costs Associated with Parkinson's Disease. Clinicoecon Outcomes Res. 2023;15:309-319. doi: 10.2147/CEOR.S398509.
   Google Scholar
• Miron B, Hawley JE, Geynisman DM, et al. Clinical Trial Considerations for Bladder Preservation in Muscle-Invasive Bladder Cancer. Advances in Oncology. 2022;2(1):213-225.
   Google Scholar
• Steinberg RL, Thomas LJ, Brooks N, et al. Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer. J Urol. May 2020;203(5):902-909. doi: 10.1097/ju.0000000000000688.
   Google Scholar
• Balar AV, Kamat AM, Kulkarni GS, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. Jul 2021;22(7):919-930. doi: 10.1016/s1470-2045(21)00147-9.
   Google Scholar
• Boorjian SA, Alemozaffar M, Konety BR, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. Jan 2021;22(1):107-117. doi: 10.1016/s1470-2045(20)30540-4.
   Google Scholar
• Chamie K, Chang SS, Gonzalgo M, et al. Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC). American Society of Clinical Oncology; 2022.
   Google Scholar
• Zlotta AR, Ballas LK, Niemierko A, et al. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol. Jun 2023;24(6):669-681. doi: 10.1016/s1470-2045(23)00170-5.
   Google Scholar
• Swinton M, Mariam NBG, Tan JL, et al. Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer. J Clin Oncol. Sep 20 2023;41(27):4406-4415. doi: 10.1200/jco.23.00725.
   Google Scholar
• Seisen T, Sun M, Lipsitz SR, et al. Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. Eur Urol. Oct 2017;72(4):483-487. doi: 10.1016/j.eururo.2017.03.038.
   Google Scholar
• Golla V, Shan Y, Farran EJ, et al. Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer. Urol Oncol. Jun 2022;40(6):273.e1-273.e9. doi: 10.1016/j.urolonc.2022.01.007.
   Google Scholar
• Durden E, Walker D, Gray S, Fowler R, Juneau P, Gooch K. The Direct and Indirect Costs Associated With Overactive Bladder Within a Commercially-Insured Population in the United States. J Occup Environ Med. Sep 2018;60(9):847-852. doi: 10.1097/JOM.0000000000001367.
   Google Scholar
• Cong Z, Tran O, Nelson J, Silver M, Chung K. Productivity Loss and Indirect Costs for Patients Newly Diagnosed with Early- versus Late-Stage Cancer in the USA: A Large-Scale Observational Research Study. Appl Health Econ Health Policy. Nov 2022;20(6):845-856. doi: 10.1007/s40258-022-00753-w.
   Google Scholar
• Parasuraman S, Thiel E, Park J, Teschemaker A. Productivity loss outcomes and costs among patients with cholangiocarcinoma in the United States: an economic evaluation. J Med Econ. Jan-Dec 2023;26(1):454-462. doi: 10.1080/13696998.2023.2187604.
   Google Scholar
• Ahlschlager L, McCabe S, Deal AM, et al. The effect of treatment on work productivity in patients with bladder cancer. Urol Oncol. Jun 2023;41(6):293.e15-293.e21. doi: 10.1016/j.urolonc.2023.01.020.
   Google Scholar
• Dormont B, Milcent C. The sources of hospital cost variability. Health Economics. 2004;13(10):927-939. doi: 10.1002/hec.935.
   Google Scholar
• Jacobs K, Roman E, Lambert J, et al. Variability drivers of treatment costs in hospitals: A systematic review. Health Policy. 2022;12(2):75-86. doi: 10.1016/j.healthpol.2021.12.004.
   Google Scholar
• Mihaylova B, Briggs A, O'Hagan A, Thompson S. Review of statistical methods for analysing healthcare resources and costs. Health Economics. 2011;20(8):897-916. doi: 10.1002/hec.1653.
   Google Scholar
• Malehi A, Pourmotahari F, Angali K. Statistical models for the analysis of skewed healthcare cost data: a simulation study. Health Economics Review. 2015;27(5) doi: 10.1186/s13561-015-0045-7.
   Google Scholar
• Geynisman DM, Broughton E, Hao Y, Zhang Y, Le T, Huo S. Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States. Urol Oncol. May 2022;40(5):195.e1-195.e11. doi: 10.1016/j.urolonc.2021.11.014.
   Google Scholar
• American Cancer Society. Key Statistics for Bladder Cancer. Accessed June 17th, 2024, https://www.cancer.org/cancer/types/bladder-cancer/about/key-statistics.html
   Google Scholar
• Malangone-Monaco E, Wilson K, Diakun D, Tayama D, Satram S, Ogale S. Cost of cystectomy-related complications in patients with bladder cancer in the United States. Curr Med Res Opin. Jul 2020;36(7):1177-1185. doi: 10.1080/03007995.2020.1758927.
   Google Scholar